Hsp90-Cdc37-IN-3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Hsp90-Cdc37-IN-3 

Hsp90-Cdc37-IN-3 (Compound 9) 是一种具有抗癌活性 (anticancer) 的新型 celastrol−imidazole 衍生物。Hsp90-Cdc37-IN-3 通过共价结合抑制 Hsp90−Cdc37，诱导细胞凋亡 (apoptosis)。

Hsp90-Cdc37-IN-3

Hsp90-Cdc37-IN-3 Chemical Structure

CAS No. : 2361009-68-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits Hsp90−Cdc37 by covalent-binding, and induces apoptosis[1].

IC50 & Target

Hsp90-Cdc37

 

体外研究
(In Vitro)

Hsp90-Cdc37-IN-3 (Compound 9) (24 h) shows broad-spectrum antitumor potential with IC50 values of 0.54, 0.59, 0.57, and 0.57 µM against A549, HTC116, U2OS, and MDA-MB231 cells, respectively[1].
Hsp90-Cdc37-IN-3 (0-5 µM, 12 h) inhibits Hsp90−Cdc37 and influences the function of apoptosis-related proteins by covalently combining with both Hsp90 and Cdc37[1].
Hsp90-Cdc37-IN-3 (0-0.8 µM, 48 h) induces apoptosis significantly in A549 cells[1].
Hsp90-Cdc37-IN-3 (0-0.4 µM, 24 h) arrests the cell cycle in the G0/G1 phase in a dose-dependent manner[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: A549
Concentration: 1.25, 2.5, and 5 µM
Incubation Time: 12 h
Result: Downregulated the levels of Hsp90−Cdc37 clients (p-Akt and Cdk4) in a dose-dependent manner, and the levels of apoptosis-related proteins (Bax, Bcl-2, cleaved caspase-3, and cleaved PARP) were significantly regulated.

Apoptosis Analysis[1]

Cell Line: A549
Concentration: 0.2, 0.4, and 0.8 μM
Incubation Time: 48 h
Result: Induced apoptosis significantly.

Cell Cycle Analysis[1]

Cell Line: A549
Concentration: 0.1, 0.2, and 0.4 μM
Incubation Time: 24 h
Result: Arrested the cell cycle in the G0/G1 phase in a dose-dependent manner.

体内研究
(In Vivo)

Hsp90-Cdc37-IN-3 (Compound 9) (0-1 mg/kg; i.p.; once a day, 21 days) shows strong antitumor activity with no significant toxicity[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c nude mice at 6 weeks old[1].
Dosage: 0.5 mg/kg or 1 mg/kg. Mice were inoculated subcutaneously with A549 cells (1*107 in 100 μL of PBS for each mouse).
Administration: Intraperitoneal injection, once a day, 21 days
Result: Decreased tumor weight and enhanced TIR without show toxicity.

分子量

638.19

Formula

C35H44ClN3O6
CAS 号

2361009-68-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Na Li, et al. Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo. J Med Chem. 2022 Mar 24;65(6):4578-4589.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复